Prenatal screening Sample: blood Result: 10 working days

SanGene NIPT Basic

SanGene NIPT Basic is a non-invasive prenatal test on the mother's blood for singleton pregnancies, from 10 completed weeks. By analysing the baby's cell-free DNA, it assesses the risk of trisomies 21, 18 and 13 (Down, Edwards and Patau syndromes) and determines the baby's sex.

Preparing for laboratory tests

Some laboratory tests require specific preparation by the patient, concerning diet before sampling and the time of day at which to come to the laboratory for sampling. The patient can be informed about this by their doctor or by the staff of Sante Laboratorije. Many other tests, however, need no prior preparation, and samples do not have to be collected at a particular time or in relation to meals.

For information, contact us on +381 11 27 62 199 | +381 64 65 87 607 or in writing at office@clinica-sante.rs.

Preparation and sampling

Preparation
Guide to preparing for tests
Sample
Blood
Results available in
10 working days
Where it is done
All laboratories and map

Description

About the test

SanGene NIPT Basic is a non-invasive prenatal screening test for singleton pregnancies. It is done on a sample of the mother's blood from 10 completed weeks of pregnancy and carries no risk for the mother or the baby. Having this information early helps in planning how the pregnancy is followed up. A separate version of the test is available for twin pregnancies.

During pregnancy, small fragments of DNA that come mainly from the placenta and reflect the baby's genetic material circulate in the mother's blood (cell-free fetal DNA). SanGene NIPT analyses them by whole-genome next-generation sequencing (paired-end NGS), so all the conditions covered by the test are assessed at the same time from a single blood sample.

This type of sequencing distinguishes the baby's DNA from the mother's DNA, which improves the estimate of the fetal fraction (the share of the baby's DNA in the sample) and the reliability of the test. According to the test's data, sensitivity and specificity for the common trisomies are above 99%, so false-positive results, and with them unnecessary invasive procedures, are rare.

The test covers:

  • Trisomy 21 (Down syndrome) – a variable degree of intellectual disability, characteristic facial features (flat facial profile, a skin fold at the inner corner of the eye, a large tongue), low muscle tone in the newborn and a single crease across the palm; heart defects are common (most often an atrioventricular septal defect), and the risk of leukaemia and early-onset Alzheimer's disease is increased.
  • Trisomy 18 (Edwards syndrome) – severe intellectual disability, restricted growth in the womb, a small skull with a prominent back of the head, low-set ears and a small lower jaw, a typical hand position (clenched fist with overlapping fingers), heart and kidney defects; life expectancy is very limited.
  • Trisomy 13 (Patau syndrome) – severe intellectual disability, a small head and brain malformations (holoprosencephaly), cleft lip and palate, extra fingers or toes (polydactyly), heart and kidney defects; most affected children die within the first year of life.
  • Baby's sex – determined from the presence of the Y chromosome in the baby's cell-free DNA.

NIPT is a screening test, not a diagnostic test: it estimates how likely it is that the baby has one of the listed conditions. A high-risk result is confirmed by a diagnostic test on amniotic fluid (amniocentesis) or on chorionic villi from the placenta (chorionic villus sampling).

When it is recommended

The test is recommended for:

  • pregnant women of any age, especially those over 35;
  • couples with a family history of chromosomal or other genetic conditions;
  • women whose other prenatal screening tests (double or triple test, fetal anomaly ultrasound scan) showed abnormal findings;
  • pregnancies conceived through IVF, including pregnancies with a donor egg and surrogate pregnancies.

International professional bodies such as the American College of Obstetricians and Gynecologists (ACOG) recommend that all pregnant women be informed about NIPT screening for the most common aneuploidies (changes in the number of chromosomes).

Preparation

  • You do not need to fast, and the sample can be taken at any time of day.
  • Sampling is by appointment; the laboratory will tell you when and where you can give the sample.
  • The test is done from 10 completed weeks of pregnancy; bring the ultrasound report confirming the stage of pregnancy and the number of babies.
  • If you have had a blood transfusion, at least 4 weeks (ideally 8 weeks) should pass before the sample is taken.
  • Tell your doctor and the laboratory if the pregnancy was conceived through IVF (especially with a donor egg), if one of the babies stopped developing in early pregnancy, or if you have had an organ transplant or stem cell treatment.

Sample

Venous blood from the mother, collected in a special tube that preserves cell-free DNA (Streck, 10 mL).

Interpreting the results

For each condition covered by the test, the result is reported as low risk or high risk; the report also states the fetal fraction.

  • Low risk – it is very unlikely that the baby has any of the conditions tested, but this cannot be ruled out completely. The test does not cover all genetic conditions and does not replace ultrasound scans in pregnancy.
  • High risk – this is not a diagnosis. Genetic counselling and confirmation by a diagnostic test (amniocentesis or chorionic villus sampling) are recommended before any decision about the pregnancy.
  • No result – occasionally the sample does not contain enough of the baby's DNA for a reliable analysis; a new blood sample is then usually needed.

Your doctor interprets the result together with your symptoms and other findings.

What can affect the result

  • Fetal fraction (the share of the baby's DNA) – if it is low, for example when the test is done earlier in pregnancy or when the mother's body weight is higher, the analysis may be less reliable or no result can be issued.
  • A baby that stopped developing – DNA from a baby that stopped developing in early pregnancy (a so-called vanished twin) can remain in the mother's blood for some time and affect the result.
  • Changes confined to the placenta – because cell-free DNA comes mainly from the placenta, a change present only in the placenta (placental mosaicism) can give a result that does not reflect the baby.
  • Organ transplant or stem cell treatment in the mother – the donor's DNA is then also present in the blood.

Related tests

  • first-trimester ultrasound scan (nuchal translucency) and fetal anomaly scan;
  • double test (first-trimester biochemical screening: free β-hCG and PAPP-A);
  • first-trimester pre-eclampsia risk assessment (PAPP-A/PlGF);
  • carrier screening of the parents for genetic conditions, for example cystic fibrosis (CFTR F508del) and hereditary deafness (GJB2 35delG);
  • amniocentesis or chorionic villus sampling, to confirm a high-risk result;
  • genetic counselling.

How to order tests online?

Add the tests you want to your cart

Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.

Pay online or at the laboratory

Payment method:

  • Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
  • At the laboratory – order your tests online and pay for them when you come to the laboratory.
Have your samples taken at one of our laboratories

After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.

Learn more
Back to top